Long-term cardiotoxicity in germ cell cancer survivors after platinum-based chemotherapy: cardiac MR shows impaired systolic function and tissue alterations.
Cardiotoxicity
Multiparametric magnetic resonance imaging
Platinum
Survivorship
Testicular neoplasms
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
20 Nov 2023
20 Nov 2023
Historique:
received:
11
05
2023
accepted:
07
09
2023
revised:
04
09
2023
pubmed:
20
11
2023
medline:
20
11
2023
entrez:
20
11
2023
Statut:
aheadofprint
Résumé
Long-term toxicities of germ cell cancer (GCC) treatment are of particular importance in young men with a life expectancy of several decades after curative treatment. This study aimed to investigate the long-term effects of platinum-based chemotherapy on cardiac function and myocardial tissue in GCC survivors by cardiac magnetic resonance (CMR) imaging. Asymptomatic GCC survivors ≥ 3 years after platinum-based chemotherapy and age-matched healthy controls underwent CMR assessment, including left ventricular (LV) and right ventricular (RV) ejection fraction (EF), strain analysis, late gadolinium enhancement (LGE) imaging, and T1/T2 mapping. Forty-four survivors (age 44 [interquartile range, IQR 37-52] years; follow-up time 10 [IQR 5-15] years after chemotherapy) and 21 controls were evaluated. LV- and RVEF were lower in GCC survivors compared to controls (LVEF 56 ± 5% vs. 59 ± 5%, p = 0.017; RVEF 50 ± 7% vs. 55 ± 7%, p = 0.008). Seven percent (3/44) of survivors showed reduced LVEF (< 50%), and 41% (18/44) showed borderline LVEF (50-54%). The strain analysis revealed significantly reduced deformation compared to controls (LV global longitudinal strain [GLS] -13 ± 2% vs. -15 ± 1%, p < 0.001; RV GLS -15 ± 4% vs. -19 ± 4%, p = 0.005). Tissue characterization revealed focal myocardial fibrosis in 9 survivors (20%) and lower myocardial native T1 times in survivors compared to controls (1202 ± 25 ms vs. 1226 ± 37 ms, p = 0.016). Attenuated LVEF was observed after two cycles of platinum-based chemotherapy (54 ± 5% vs. 62 ± 5%, p < 0.001). Based on CMR evaluation, combination chemotherapy with cumulative cisplatin ≥ 200 mg/m Platinum-based chemotherapy is associated with decreased systolic function, non-ischemic focal myocardial scar, and decreased T1 times in asymptomatic long-term germ cell cancer survivors. Clinicians should be particularly aware of the risk of cardiac toxicity after platinum-based chemotherapy. • Platinum-based chemotherapy is associated with attenuation of biventricular systolic function, lower myocardial T1 relaxation times, and non-ischemic late gadolinium enhancement. • Decreased systolic function and non-ischemic late gadolinium enhancement are associated with a cumulative cisplatin dose of ≥ 200 mg/m
Identifiants
pubmed: 37982836
doi: 10.1007/s00330-023-10420-w
pii: 10.1007/s00330-023-10420-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023. The Author(s).
Références
Hanna N, Einhorn LH (2014) Testicular cancer: a reflection on 50 years of discovery. J Clin Oncol 32:3085–3092
doi: 10.1200/JCO.2014.56.0896
pubmed: 25024068
Beyer J, Collette L, Sauvé N et al (2021) Survival and new prognosticators in metastatic seminoma: results from the IGCCCG-update consortium. J Clin Oncol 39:1553–1562
doi: 10.1200/JCO.20.03292
pubmed: 33729863
pmcid: 8099394
Gillessen S, Sauvé N, Collette L et al (2021) Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG update consortium. J Clin Oncol 39:1563–1574
doi: 10.1200/JCO.20.03296
pubmed: 33822655
pmcid: 8099402
Chovanec M, Lauritsen J, Bandak M et al (2021) Late adverse effects and quality of life in survivors of testicular germ cell tumour. Nat Rev Urol 18:227–245
doi: 10.1038/s41585-021-00440-w
pubmed: 33686290
Belt-Dusebout AWvd, Nuver J, Wit Rd et al (2006) Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 24:467–475
doi: 10.1200/JCO.2005.02.7193
pubmed: 16421423
Haugnes HS, Wethal T, Aass N et al (2010) Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 28:4649–4657
doi: 10.1200/JCO.2010.29.9362
pubmed: 20855830
Huddart RA, Norman A, Shahidi M et al (2003) Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21:1513–1523
doi: 10.1200/JCO.2003.04.173
pubmed: 12697875
Lauritsen J, Hansen MK, Bandak M et al (2020) Cardiovascular risk factors and disease after male germ cell cancer. J Clin Oncol 38:584–592
doi: 10.1200/JCO.19.01180
pubmed: 31821065
Bjerring AW, Fosså SD, Haugnes HS et al (2021) The cardiac impact of cisplatin-based chemotherapy in survivors of testicular cancer: a 30-year follow-up. Eur Heart J Cardiovasc Imaging 22:443–450
doi: 10.1093/ehjci/jeaa289
pubmed: 33152065
Altena R, Hummel YM, Nuver J et al (2011) Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer. Ann Oncol 22:2286–2293
doi: 10.1093/annonc/mdr408
pubmed: 21878427
Nuver J, Smit AJ, Sleijfer DT et al (2005) Left ventricular and cardiac autonomic function in survivors of testicular cancer. Eur J Clin Invest 35:99–103
doi: 10.1111/j.1365-2362.2005.01460.x
pubmed: 15667580
Altena R, de Haas EC, Nuver J et al (2009) Evaluation of sub-acute changes in cardiac function after cisplatin-based combination chemotherapy for testicular cancer. Br J Cancer 100:1861–1866
doi: 10.1038/sj.bjc.6605095
pubmed: 19455138
pmcid: 2714243
van Schinkel LD, Willemse PM, van der Meer RW et al (2013) Chemotherapy for testicular cancer induces acute alterations in diastolic heart function. Br J Cancer 109:891–896
doi: 10.1038/bjc.2013.445
pubmed: 23922115
pmcid: 3749589
Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH (2014) Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging 15:324–331
doi: 10.1093/ehjci/jet159
pubmed: 24057661
Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH (2014) Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol 63:2751–2768
doi: 10.1016/j.jacc.2014.01.073
pubmed: 24703918
Lyon AR, López-Fernández T, Couch LS et al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. https://doi.org/10.1093/eurheartj/ehac244
doi: 10.1093/eurheartj/ehac244
pubmed: 36017568
Liu JE, Barac A, Thavendiranathan P, Scherrer-Crosbie M (2020) Strain imaging in cardio-oncology. JACC CardioOncol 2:677–689
doi: 10.1016/j.jaccao.2020.10.011
pubmed: 34396282
pmcid: 8352045
Narayan HK, French B, Khan AM et al (2016) Noninvasive measures of ventricular-arterial coupling and circumferential strain predict cancer therapeutics-related cardiac dysfunction. JACC Cardiovasc Imaging 9:1131–1141
doi: 10.1016/j.jcmg.2015.11.024
pubmed: 27085442
pmcid: 5055405
Jeong D, Gladish G, Chitiboi T, Fradley MG, Gage KL, Schiebler ML (2019) MRI in cardio-oncology: a review of cardiac complications in oncologic care. J Magn Reson Imaging 50:1349–1366
doi: 10.1002/jmri.26895
pubmed: 31448472
Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129–2200
doi: 10.1093/eurheartj/ehw128
pubmed: 27206819
Tahir E, Azar M, Shihada S et al (2022) Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy-related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT. Eur Radiol 32:1853–1865
doi: 10.1007/s00330-021-08260-7
pubmed: 34536111
Schulz-Menger J, Bluemke DA, Bremerich J et al (2013) Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task force on standardized post processing. J Cardiovasc Magn Reson 15:35
doi: 10.1186/1532-429X-15-35
pubmed: 23634753
pmcid: 3695769
Kellman P, Wilson JR, Xue H, Ugander M, Arai AE (2012) Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method. J Cardiovasc Magn Reson 14:63
doi: 10.1186/1532-429X-14-63
pubmed: 22963517
pmcid: 3441905
Morais P, Marchi A, Bogaert JA et al (2017) Cardiovascular magnetic resonance myocardial feature tracking using a non-rigid, elastic image registration algorithm: assessment of variability in a real-life clinical setting. J Cardiovasc Magn Reson 19:24
doi: 10.1186/s12968-017-0333-y
pubmed: 28209163
pmcid: 5314711
Ma H, Jones KR, Guo R, Xu P, Shen Y, Ren J (2010) Cisplatin compromises myocardial contractile function and mitochondrial ultrastructure: role of endoplasmic reticulum stress. Clin Exp Pharmacol Physiol 37:460–465
doi: 10.1111/j.1440-1681.2009.05323.x
pubmed: 19878217
Hellesnes R, Myklebust TÅ, Fosså SD et al (2021) Testicular cancer in the cisplatin era: causes of death and mortality rates in a population-based cohort. J Clin Oncol 39:3561–3573
doi: 10.1200/JCO.21.00637
pubmed: 34388002
Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145:e876–e894
pubmed: 35363500
Modi K, Joppa S, Chen KA et al (2021) Myocardial damage assessed by late gadolinium enhancement on cardiovascular magnetic resonance imaging in cancer patients treated with anthracyclines and/or trastuzumab. Eur Heart J Cardiovasc Imaging 22:427–434
doi: 10.1093/ehjci/jeaa279
pubmed: 33211843
Domenech-Ximenos B, Sanz-de la Garza M, Prat-González S et al (2020) Prevalence and pattern of cardiovascular magnetic resonance late gadolinium enhancement in highly trained endurance athletes. J Cardiovasc Magn Reson 22:62
doi: 10.1186/s12968-020-00660-w
pubmed: 32878630
pmcid: 7469354
Turkbey EB, Nacif MS, Guo M et al (2015) Prevalence and correlates of myocardial scar in a US cohort. JAMA 314:1945–1954
doi: 10.1001/jama.2015.14849
pubmed: 26547466
pmcid: 4774246
LotaAmrit S, Tsao A, Owen R et al (2021) Prognostic significance of nonischemic myocardial fibrosis in patients with normal LV volumes and ejection-fraction. JACC Cardiovasc Imaging 14:2353–2365
doi: 10.1016/j.jcmg.2021.05.016
Muehlberg F, Funk S, Zange L et al (2018) Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy. ESC Heart Fail 5:620–629
doi: 10.1002/ehf2.12277
pubmed: 29673122
pmcid: 6073029
Radenkovic D, Weingärtner S, Ricketts L, Moon JC, Captur G (2017) T1 mapping in cardiac MRI. Heart Fail Rev 22:415–430
doi: 10.1007/s10741-017-9627-2
pubmed: 28623475
pmcid: 5487768